MindMaze Therapeutics Holding SA
MMTX.S operates in the healthcare diagnostics segment, providing specialized diagnostic solutions and related services.
Business. MMTX.S is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through a product-sale model, focusing on activities related to healthcare diagnostics. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MMTX.S is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through a product-sale model, focusing on activities related to healthcare diagnostics. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
MMTX.S exhibits a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a purely equity-funded operation. The company holds CHF 9.47 million in cash and equivalents, which is a significant portion of its total assets of CHF 51.53 million. However, the company's liquidity is rated as low, and its operating cash flow is negative at CHF -7.21 million, suggesting ongoing cash burn.
Profitability metrics are negative, with a return on equity of -25.84% and a return on assets of -19.22%, both well below the industry norms for a biotechnology firm. The company reported a net loss of CHF 9.91 million and an operating loss of CHF 10.52 million, indicating a lack of operational profitability.
The company's revenue is concentrated in a single segment, as no segmental breakdown is provided in the available data. There is no indication of geographic diversification, and the company's exposure to regional markets is not disclosed.
Looking ahead, the company is expected to continue its negative earnings trajectory, with a mean EPS estimate of -0.08 CHF and a mean revenue estimate of 5.5 million CHF for the upcoming period. The company's historical revenue of CHF 642 million and the negative operating cash flow suggest a challenging growth environment.
The risk assessment indicates low dilution and liquidity risks, with no immediate filing-based flags detected. However, the company's negative free cash flow of CHF -14.51 million and capital expenditure of CHF -6.24 million suggest ongoing investment and operational challenges.
Recent financial filings and transcripts do not indicate any significant events that would alter the company's current trajectory. The company's financial health remains underpinned by its cash reserves, but the lack of profitability and ongoing cash outflows remain critical concerns.
- MMTX.S is a biotechnology company with a negative return on equity and assets, indicating poor profitability.
- The company is entirely equity-funded with no long-term debt, but it has a low liquidity rating.
- MMTX.S has no disclosed segmental or geographic diversification, suggesting high concentration risk.
- Analysts expect continued negative earnings and a decline in revenue for the upcoming period.
- The company's capital expenditures and free cash flow are negative, indicating ongoing investment and operational challenges.
- There are no immediate liquidity or dilution risks based on the latest filings and disclosures.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,08 |
| Revenue | —no estimate | —no estimate | 5,5M CHF |
| Operating income | —no estimate | —no estimate | -12,2M CHF |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- 10% owner · Warrants to purchase Ordinary Shares → Ordinary SharesAcquired 9 000 @ $11,50purchase · 2025-10-28
- 10% owner · Warrants to purchase Ordinary Shares → Ordinary SharesAcquired 194 100 @ $11,50purchase · 2025-10-24
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MMTX.S Market data — financials · 2026-05-28
- MindMaze Therapeutics Holding SA Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- 10% owner · Ordinary SharesOther 10 000 · 2026-02-25
- See Remarks · Ordinary SharesOther 10 000 · 2026-02-25
- 10% owner · Ordinary SharesOther 10 000 @ $1,00$10K · 2026-02-25
- Director, See Remarks, 10% owner · Ordinary SharesOther 1 848 100 · 2025-11-12
- 10% owner · Ordinary SharesBought 9 000 · 2025-10-28
- 10% owner · Ordinary SharesBought 194 100 · 2025-10-24
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 65.80xDerived (calculated)
- Current ratio (FY 2025-12-31): 14.82xDerived (calculated)
- Current liabilities (annual): USD 50.75KSEC XBRL filing
- Total liabilities (annual): USD 740.75KSEC XBRL filing
- Shares outstanding (annual): 1.93MSEC XBRL filing
- Current assets (annual): USD 752.01KSEC XBRL filing
- Shareholders' equity (annual): USD 11.26KSEC XBRL filing
- Total assets (annual): USD 70.22MSEC XBRL filing